Insider · CIK 0001800013
Mark Christopher Murray
officer
Files at CE (Celanese Corp). First filing Mar 10, 2025, latest May 28, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
2 / 0
$205k bought, $0 sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CE: Celanese Corp
CEOct 9, 2026 · close 45.02
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 39Weak | CEbuy Celanese Corp | $77k 1,479 shares | +11% | +40% from low-62% from high | |
| 47Moderate | Celanese Corp | $128k 2,353 shares | +20% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 23, 2025 | CE Celanese Corp | POpen-market purchase Common Stock | +1,479 | $52.18 | $77k | 15,468 | May 28, 2025 |
| Mar 7, 2025 | CE Celanese Corp | POpen-market purchase Common Stock | +2,353 | $54.45 | $128k | 13,989 | Mar 10, 2025 |
| Feb 26, 2025 | CE Celanese Corp | AGrant or award Nonqualified Stock Option (right to buy)derivative | +19,027 | $0.00 | $0 | 19,027 | Feb 28, 2025 |
| Feb 15, 2025 | CE Celanese Corp | AGrant or award Common Stock | +871 | $0.00 | $0 | 12,000 | Feb 19, 2025 |
| Feb 15, 2025 | CE Celanese Corp | FTax withholding Common Stock | -364 | $69.13 | $25k | 11,636 | Feb 19, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.